Published in Eur J Med Chem on June 27, 2008
Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. J Med Chem (2009) 1.04
Butyrate histone deacetylase inhibitors. Biores Open Access (2012) 0.90
Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei. Bioorg Med Chem Lett (2012) 0.88
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol (2005) 4.54
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol (2002) 4.45
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature (2012) 4.08
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J (2008) 3.86
Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril (2004) 2.67
ATM activation in normal human tissues and testicular cancer. Cell Cycle (2005) 2.25
Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol (2003) 2.25
Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics (2006) 1.73
Validation of the Oscar 2 oscillometric 24-h ambulatory blood pressure monitor according to the British Hypertension Society protocol. Blood Press Monit (2007) 1.66
Comparative estimation of anterior chamber depth by ultrasonography, Orbscan II, and IOLMaster. J Cataract Refract Surg (2004) 1.41
Human Xip1 (C2orf13) is a novel regulator of cellular responses to DNA strand breaks. J Biol Chem (2007) 1.38
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther (2006) 1.37
Culprit and victim -- DNA topoisomerase II. Lancet Oncol (2002) 1.26
Validation of the OSCAR 2 oscillometric 24-hour ambulatory blood pressure monitor according to the International Protocol for the validation of blood pressure measuring devices. Blood Press Monit (2004) 1.25
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc (2014) 1.23
A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc (2011) 1.22
Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun (2008) 1.16
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology (2009) 1.14
A comparison of the Constant and Oxford shoulder scores in patients with conservatively treated proximal humeral fractures. J Shoulder Elbow Surg (2007) 1.14
Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. J Mol Biol (2006) 1.14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem (2012) 1.09
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem (2013) 1.09
Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res (2006) 1.09
MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res (2006) 1.08
Reliability and validity of cervical auscultation: a controlled comparison using videofluoroscopy. Dysphagia (2004) 1.07
Development of homogeneous luminescence assays for histone demethylase catalysis and binding. Anal Biochem (2010) 1.07
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology (2008) 1.07
Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One (2010) 1.06
The roles of Jumonji-type oxygenases in human disease. Epigenomics (2014) 1.05
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther (2010) 1.04
Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol (2013) 1.04
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer (2013) 1.03
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res (2005) 1.02
Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol (2003) 1.01
Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J Cancer (2004) 1.01
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol (2002) 0.97
Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates. Org Biomol Chem (2010) 0.97
Tissue uptake of thyroid hormone by amino acid transporters. Best Pract Res Clin Endocrinol Metab (2007) 0.94
Reevaluation of the PPAR-beta/delta ligand binding domain model reveals why it exhibits the activated form. Mol Cell (2006) 0.94
Linking of 2-oxoglutarate and substrate binding sites enables potent and highly selective inhibition of JmjC histone demethylases. Angew Chem Int Ed Engl (2012) 0.94
Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med (2002) 0.94
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol (2006) 0.93
Plasmodium subtilisin-like protease 1 (SUB1): insights into the active-site structure, specificity and function of a pan-malaria drug target. Int J Parasitol (2012) 0.93
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer (2010) 0.92
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem (2013) 0.91
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J Med Chem (2013) 0.91
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS (2011) 0.90
Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem (2003) 0.90
Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei. Bioorg Med Chem Lett (2012) 0.88
Distractibility in Attention/Deficit/ Hyperactivity Disorder (ADHD): the virtual reality classroom. Child Neuropsychol (2008) 0.88
A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction. Angew Chem Int Ed Engl (2014) 0.88
Popliteal block with transfibular approach in ankle arthrodesis: a case series. J Med Case Rep (2010) 0.87
Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs (2009) 0.86
Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. J Enzyme Inhib Med Chem (2009) 0.86
Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol (2006) 0.84
G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem Pharmacol (2002) 0.84
Mildronate treatment alters γ-butyrobetaine and l-carnitine concentrations in healthy volunteers. J Pharm Pharmacol (2011) 0.84
Prediction of in vitro metabolic stability of calcitriol analogs by QSAR. J Comput Aided Mol Des (2003) 0.83
Quantitative analysis of histone demethylase probes using fluorescence polarization. J Med Chem (2013) 0.83
Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. J Biol Chem (2005) 0.83
Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance. Biochemistry (2002) 0.83
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer (2008) 0.83
Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark (2008) 0.83
A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem (2014) 0.83
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. Br J Pharmacol (2009) 0.82
[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. PLoS One (2013) 0.82
Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res (2005) 0.81
Eradication of methicillin-resistant Staphylococcus aureus from pressure sores using warming therapy. Surg Infect (Larchmt) (2003) 0.81
Prediction of drug efficacy for cancer treatment based on comparative analysis of chemosensitivity and gene expression data. Bioorg Med Chem (2011) 0.81
A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo. Mol Pharmacol (2007) 0.81
A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol Pharmacol (2006) 0.81
[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice. PLoS One (2012) 0.81
Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. Neurosci Lett (2009) 0.81
Complex regulation of thyroid hormone action: multiple opportunities for pharmacological intervention. Pharmacol Ther (2002) 0.81
Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression. Medicina (Kaunas) (2013) 0.81
A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells. J Biol Chem (2004) 0.81
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha. FEBS Lett (2002) 0.81
The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov Today (2003) 0.81
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol (2005) 0.81
Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model. Cell Biochem Funct (2011) 0.81
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. J Med Chem (2013) 0.80